We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
+20.9%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$921M
AUM Growth
+$477M
Cap. Flow
+$408M
Cap. Flow %
44.33%
Top 10 Hldgs %
97.69%
Holding
17
New
2
Increased
2
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$388M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$38.4M
3
KURA icon
Kura Oncology
KURA
+$17.6M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$3.4M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$17.2M
2
ABUS icon
Arbutus Biopharma
ABUS
+$10.4M
3
VYGR icon
Voyager Therapeutics
VYGR
+$5.51M
4
CYTK icon
Cytokinetics
CYTK
+$4.32M
5
PANA.U
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
+$1.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$385M 41.79%
+9,671,643
New +$388M
KROS icon
2
Keros Therapeutics
KROS
$199M
$99.7M 10.82%
1,412,705
– –
RLAY icon
3
Relay Therapeutics
RLAY
$4.1B
$88.9M 9.66%
2,139,380
– –
ALXO icon
4
ALX Oncology
ALXO
$261M
$83.9M 9.12%
973,514
– –
NRIX icon
5
Nurix Therapeutics
NRIX
$2.41B
$77.2M 8.39%
2,347,804
-210
-0% -$6.96K
KURA icon
6
Kura Oncology
KURA
$800M
$59M 6.41%
1,807,982
+500,000
+38% +$17.6M
OLMA icon
7
Olema Pharmaceuticals
OLMA
$1B
$39.3M 4.27%
+818,030
New +$38.4M
CYTK icon
8
Cytokinetics
CYTK
$10.5B
$29.8M 3.24%
1,435,992
-236,300
-14% -$4.32M
GBIO
9
DELISTED
Generation Bio
GBIO
$24.3M 2.64%
85,794
– –
PCVX icon
10
Vaxcyte
PCVX
$7.81B
$12.4M 1.34%
465,821
– –
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$10.3M 1.11%
1,787,094
– –
ACRS icon
12
Aclaris Therapeutics
ACRS
$726M
$6.16M 0.67%
951,384
+806,510
+557% +$3.4M
PNT
13
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$4.87M 0.53%
350,000
– –
ABUS icon
14
Arbutus Biopharma
ABUS
$857M
– –
-3,332,616
Closed -$10.4M
VYGR icon
15
Voyager Therapeutics
VYGR
$183M
– –
-516,751
Closed -$5.51M
PANA.U
16
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
– –
-150,000
Closed -$1.8M
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-126,492
Closed -$17.2M

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return
WW
Windle Wealth Oklahoma City, Oklahoma $237M AUM 22.79% 1-Year Est. Return
CB
CNB Bank Clearfield, Pennsylvania $238M AUM 26.55% 1-Year Est. Return

Foresite Capital Management IV's Q4 2020 Portfolio in Review

As of Q4 2020, Foresite Capital Management IV held 17 positions worth $921M, up 108% from $443M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Foresite Capital Management IV deployed $408M of net new capital in Q4 2020, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Kinnate Biopharma Inc. Common Stock: 9,671,643 shares worth $385M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $4.32M trimmed.

  • Foresite Capital Management IV's largest Q4 2020 buy was Kinnate Biopharma Inc. Common Stock: 9,671,643 shares worth $385M.
  • Foresite Capital Management IV added most to Kura Oncology in Q4 2020, an estimated $17.6M increase.
  • Foresite Capital Management IV's biggest Q4 2020 reduction was Cytokinetics, cutting an estimated $4.32M.
  • Foresite Capital Management IV fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $17.2M.
  • Foresite Capital Management IV's ten largest holdings make up 98% of its $921M portfolio in Q4 2020.
  • Foresite Capital Management IV opened 2 new positions and closed 4 in Q4 2020.
  • Foresite Capital Management IV's portfolio value rose 108% quarter-over-quarter to $921M.

Based on Foresite Capital Management IV's 13F filing for Q4 2020, filed 16 Feb 2021.